Latest / CME Outfitters Medical Education / Beyond VEGF: Understanding Blood-Retinal Barrier Biology and Emerging Mechanisms in DME and Neovascular AMD
Transcript
- 0:10SPEAKER_01: All right.
- 0:10SPEAKER_01: Well, welcome everyone.
- 0:11SPEAKER_01: Thank you all for coming on a Sunday night with us.
- 0:14SPEAKER_01: Uh it's really great to be here in New Orleans.
- 0:16SPEAKER_01: I hope you had a great academy.
- 0:18SPEAKER_01: Uh this is a really neat program, probably one of the first times we've you've seen some of this data, seen some of this information.
- 0:24SPEAKER_01: This is Beyond VEGEF, understanding blood retinal barrier biology and merging mechanisms in both diabetic maculedema and neovascular AMD.
- 0:31SPEAKER_01: This activity is supported by a CME grant to CME outfitters and supported through an educational grant from Merck Company Incorporated.
- 0:39SPEAKER_01: So we're going to discuss uh some of the products and devices that are not currently labeled or approved by the FDA.
- 0:45SPEAKER_01: Some of them are investigational.
- 0:47SPEAKER_01: That will be important to see.
- 0:48SPEAKER_01: And we might discuss them off-label items, so we will be informing you on when we do discuss them tonight.
- 0:53SPEAKER_01: So I am Rishi Singh, I'm the chair of the program today.
- 0:56SPEAKER_01: Uh I'm also the chair of ophthalmology at Mass INER and Harvard Medical School in Boston, Massachusetts, and I'm joined by my friend and colleague, Dr.
- 1:02SPEAKER_01: Robert Avery, founder of California Retina Consultants and Retina Consultants America in Santa Barbara, California.
- 1:08SPEAKER_01: Bob, welcome to the program.
- 1:10SPEAKER_01: Thank you.
- 1:10SPEAKER_01: Happy to be here.
- 1:11SPEAKER_01: He's an expert in the field.
- 1:12SPEAKER_01: Love to have him here.
- 1:13SPEAKER_01: So these are the three learning objectives we're going to cover tonight.
- 1:16SPEAKER_01: The first is to evaluate the cellular and molecular mechanisms by which the blood retinal barrier breakdown drives vascular leakage and vision loss in both neovascular AMD and diabetic macledema.
- 1:27SPEAKER_01: We know this is really the underlying pathogenesis of diabetes.
- 1:30SPEAKER_01: Many of us sometimes forget that these cells that we look at, parasites and vascular endothelium, are really part of why diabetes develops in the first place.
- 1:39SPEAKER_01: What if we had a drug to prevent the blood retinal barrier breakdown?
- 1:43SPEAKER_01: We'll talk about that tonight, I think, in very many stages of what we can offer patients from a mechanistic standpoint.
- 1:48SPEAKER_01: We're going to assess the uh route of emerging therapeutic approaches to BRB stabilization and vascular regulation.
- 1:56SPEAKER_01: You know, VantivEGF therapy has been with us for over 20 years now.
- 1:59SPEAKER_01: And obviously it's helped with the vascular component, but it really doesn't address the underlying blood retinal barrier component.
- 2:05SPEAKER_01: We'll talk about why that matters in patients in a moment.
- 2:08SPEAKER_01: And we'll identify some suboptimal outcomes in our patients.
- 2:10SPEAKER_01: We know with this from practice.
- 2:12SPEAKER_01: You know, a lot of us take care of patients with DME and not neovascular AMD, and they don't always end up with the best vision.
- 2:19SPEAKER_01: Sometimes they lose vision after initial results they got.
- 2:23SPEAKER_01: And sometimes, you know, the long-term information can really be quite poor.
- 2:27SPEAKER_01: And we'll kind of cover a lot of that data in just a moment to kind of frame and reference what newer therapies may offer and how we can use evidence in that to handle that.
- 2:36SPEAKER_01: So this is a really common slide.
- 2:38SPEAKER_01: You've probably seen it a lot, but it goes to tell you about kind of like the longevity of a patient for neovascular AMD on the left side in Vestrement iris.
- 2:47SPEAKER_01: Vestrement iris are two very well-known registries, databases that are out there.
- 2:51SPEAKER_01: And what you can see first and foremost is that there's a high frequency of injections per year.
- 2:55SPEAKER_01: We're talking about eight to six in a year's time frame for the first two or three years, but you can see it tails off as time goes on.
- 3:02SPEAKER_01: Well, that might be durability, that might be control, but what you ultimately see on the right side is the loss of vision in these patients over time.
- 3:10SPEAKER_01: And so while we have this great, you know, sort of initial burst of improvement maybe that happens with anti-veg F therapy, um, we see that over time the long-term outcomes appear to be drifting downward, and that is not a good thing.
- 3:23SPEAKER_01: And so we have to find other opportunities, maybe other therapeutic options, ways of making sure the vision loss doesn't occur over time.
- 3:30SPEAKER_01: This is multifactorial, it's not just one thing, right?
- 3:33SPEAKER_01: It's sometimes it's inadequate treatment, sometimes it's uh inadequate control.
- 3:38SPEAKER_01: We try to extend patients sometimes for the risk of more durability, and and sometimes it's from macular atrophy, which is not controllable right now.
- 3:47SPEAKER_01: And so we will talk a little bit about some of those theories and thoughts in just a moment.
- 3:51SPEAKER_01: So why does this gap persist?
- 3:53SPEAKER_01: I kind of talked about some of this uh just a moment ago, but let's breaking it down kind of into three components.
- 3:59SPEAKER_01: The first is maybe not enough drug.
- 4:01SPEAKER_01: This last couple years we've had some newer drugs come out, higher dose options for patients.
- 4:05SPEAKER_01: You've heard of them, I'm sure.
- 4:06SPEAKER_01: Those are really ways of addressing the thing that we don't have, maybe enough drug on board.
- 4:11SPEAKER_01: The second is maybe the wrong target, right?
- 4:13SPEAKER_01: So VEGF A has been the target we've had all along.
- 4:16SPEAKER_01: Then we've gone on to angiopuetin II, which is sort of the newer target.
- 4:20SPEAKER_01: We know that it's sort of the synergistic effect with VEGFA inhibition.
- 4:24SPEAKER_01: And finally, it's the thing that's too late.
- 4:26SPEAKER_01: Maybe what it what happens essentially is we have so much structural damage from the yin and the yang of the retina over time.
- 4:32SPEAKER_01: The fluid goes on and off in the retina over time.
- 4:34SPEAKER_01: Maybe that's the reason why photoreceptors are lost and you have inner and outer retinal atrophy that occurs.
- 4:40SPEAKER_01: And so those are some of the things we have to consider when we look at this.
- 4:43SPEAKER_01: Uh you you the middle panel shows you really nicely and in a very good way of sort of the regulatory effects we have in the eye.
- 4:50SPEAKER_01: So, regulatory-wise, normally we don't have VEGF in every eye.
- 4:54SPEAKER_01: We we have VEGF when you obviously have vasculogenesis, which is the early part of being a newborn and developing the vessels.
- 5:00SPEAKER_01: But once the vessels are uh older in the patient, there's a probably a baseline level of VEGF, but it's not to the pathological levels.
- 5:08SPEAKER_01: But you have a high level of what we what is also another cytokine called angiopuitin 1.
- 5:13SPEAKER_01: It's the good actor in vascular stability.
- 5:16SPEAKER_01: Vascular stability is obviously important for patients.
- 5:18SPEAKER_01: So angiopuetin 1 plays that role, and it outweighs angiopuitin 2, which is again the bad actor that occurs when there's higher levels of VEGF.
- 5:26SPEAKER_01: In the middle panel, in the right panel, you see what happens essentially when you have conditions like neovascular AMD and diabetic retinopathy.
- 5:33SPEAKER_01: That's when angiopuetin II gets higher than angiopuetin 1, so it displaces its receptor on patients.
- 5:39SPEAKER_01: And you also have an increase in VEGF in these patients.
- 5:41SPEAKER_01: So you have both of them working synergistically to basically break down the blood retinal barrier and also cause angiogenesis in these patient populations in pathological states.
- 5:50SPEAKER_01: And we'll go into this a little bit more in detail later, but I think this is a nice slide to kind of show you how the cytokines take over and what they do.
- 5:57SPEAKER_01: So the first learning objective was again to evaluate the cellular molecular mechanisms by which the blood retinal barrier breakdown drives leakage.
- 6:04SPEAKER_01: And so let's get into that and start with a question for you all.
- 6:07SPEAKER_01: So, which of the statement best describes the primary role of the blood retinal barrier in patients?
- 6:31SPEAKER_01: Okay, so the answers you gave were it selectively regulates what passes between the circulation and the neural retina, which is absolutely correct.
- 6:39SPEAKER_01: That's good.
- 6:40SPEAKER_01: So many very informed people in the audience.
- 6:42SPEAKER_01: So let's do a case to kind of illustrate what that looks like in a patient.
- 6:45SPEAKER_01: So I'm gonna ask Dr.
- 6:47SPEAKER_01: Avery to weigh in here.
- 6:48SPEAKER_01: So this is 67-year-old male that we see in clinic, Bob, 14 years of type 2 diabetes, A1C of 8.4%, blood pressures controlled on an ACE inhibitor, reduced for reduced uh referred for reduced reading.
- 6:59SPEAKER_01: That's the OCT present there.
- 7:01SPEAKER_01: Um bilateral center involving DME, no prior uh intravitual therapy.
- 7:06SPEAKER_01: Uh why don't you tell me a little bit of what you see in the OCT?
- 7:09SPEAKER_01: What makes you trick pick which drug for this patient potentially based upon the vision, which is 22060, retinal thickness of 490, and some OCT findings there?
- 7:20SPEAKER_00: Well, there's there is uh obviously swelling in the center.
- 7:23SPEAKER_00: There's some subretinal fluid, there's intra-retinal fluid.
- 7:26SPEAKER_00: Looks like a mild epiretinal membrane, but it doesn't seem bad enough.
- 7:29SPEAKER_00: I mean, sometimes uh epiretinal membranes with traction or severe uh membranes can really inhibit the ability of the anti-vegfs and other agents to flatten the retina.
- 7:38SPEAKER_00: But this one seems mild for me right now.
- 7:40SPEAKER_00: I would just go forth with uh primary therapy, and uh that's either anti-vegf or depending on where you uh uh where you are with insurance, uh you could go to a combination as well, like something like FirstMab.
- 7:53SPEAKER_00: Uh but uh I think most uh of America you start with step therapy and that might be bevacismab.
- 8:00SPEAKER_00: Uh but uh you know the other agents uh actually dry better.
- 8:05SPEAKER_00: In my opinion, you know, bevacismab is sort of the weakest at drying, but it it does work if you're given frequently quite well.
- 8:12SPEAKER_00: But uh the other agents like uh you know, we had a business map drives a little better, and then a flibricep dries a little better, and then Parisimab dries a little better.
- 8:20SPEAKER_00: So that's the the the sequence and depends on where you are with your uh insurance status.
- 8:26SPEAKER_01: Yeah, absolutely.
- 8:27SPEAKER_01: Uh this is obviously sometimes not driven by us as much as the the insurance companies around us, but there are a couple of interesting findings on the OCT, as you pointed out, so thank you for pointing this out.
- 8:36SPEAKER_01: But if you look temporal, you see that entire inner retina has this hyperreflective band that's called drill or dissociation of retinal inner layers.
- 8:44SPEAKER_01: You have the spongiform sort of retinal appearance, you have cystic changes in the retina, you even have a touch of maybe subretinal fluid just centrally there.
- 8:52SPEAKER_01: So these are all really good factors to look at when you look at an OCT to tell you, you know, where on the realm of severity level this has.
- 8:59SPEAKER_01: This is not just a little bit of fluid centrally, this is a broad amount of fluid that you can see on the OCT.
- 9:04SPEAKER_01: Vision obviously compromised, visual acuity in the left eye is 2030, retinal thickness is 334.
- 9:10SPEAKER_01: And again, this patient got three monthly bevisamab injections, pretty commonly, again, off-label treatment that we give to a lot of patients.
- 9:17SPEAKER_01: Then three monthly two milligram injections uh because of uh not having the right response.
- 9:23SPEAKER_01: They were switched back, uh they were switched to a flipper sept at month three for lack of response, and they got all six injections.
- 9:30SPEAKER_01: Now your retinal thickness at the end of this is 442 and 2050 vision at month seven.
- 9:35SPEAKER_01: So what are you thinking, Bob, as far as the response in this patient?
- 9:39SPEAKER_01: What would you kind of classify this response as?
- 9:41SPEAKER_00: Well, it does not seem to be satisfactory to me.
- 9:44SPEAKER_00: He you if if these injections are given at an appropriate time frame, and it seems like they have been.
- 9:49SPEAKER_00: Unfortunately, in the clinic, sometimes they have to be extended due to scheduling.
- 9:53SPEAKER_00: You're out of town, they're out of town, and but it seems like he got these as scheduled, so he's met that criterion.
- 9:58SPEAKER_00: And so uh you know, you could change to something that attacks two pathways, such as First Mab.
- 10:04SPEAKER_00: Uh if that fails, you could change to add steroids if uh if the patient uh you know doesn't have a contraindication like severe glaucoma or something.
- 10:12SPEAKER_01: Yeah, and I'm gonna leave you with this last line here, which I think is if you you know walk away tonight, kind of think about this on uh when you go back to the clinic next week.
- 10:20SPEAKER_01: Fewer than five letters gain and less than 10% reduction in retinal thickness.
- 10:24SPEAKER_01: That's a pretty well-established non-response definition.
- 10:27SPEAKER_01: It's been around for a while.
- 10:28SPEAKER_01: Um I've authored a couple papers on sort of non-responsive after anti-vegf treatments, some of the larger studies, but that's one I think is very important.
- 10:36SPEAKER_01: That kind of gives you a sense of like how the patient's doing overall.
- 10:39SPEAKER_01: Um, this patient's been adherent and we've tried to dry them.
- 10:42SPEAKER_01: Let's go with you guys.
- 10:43SPEAKER_01: What do you guys think about um what the issue is here?
- 10:47SPEAKER_01: Is he he's adherent on the schedule, six injections, two anti-vegf agents, cellul center involving edema.
- 10:53SPEAKER_01: What best explains it?
- 10:54SPEAKER_01: So go ahead and answer for us.
- 11:14SPEAKER_01: All right.
- 11:14SPEAKER_01: So you said that it's the wrong target.
- 11:16SPEAKER_01: Signals other than VEGFA are holding the barrier open.
- 11:19SPEAKER_01: Okay, that's great.
- 11:20SPEAKER_01: So yeah, obviously we have newer drugs available.
- 11:22SPEAKER_01: We have higher dose drugs.
- 11:23SPEAKER_01: We've got angiopoitin II inhibitors, and potentially there are other drugs down the pipeline, which we'll go over later in the program, which I think will be valuable to look at.
- 11:31SPEAKER_01: Um, the barrier is important to talk about here, and this is one I think is very important.
- 11:35SPEAKER_01: Obviously, when we learned about diabetes and diabetic retinopathy, we learned about the cells that are involved in the vasculature, right?
- 11:43SPEAKER_01: So, first of all, there's the endothelial cells, these are tight junctions which are basically lining the endothelium that close this off, so preventing leakage within the extravascular space or the intraetinal space, whichever you want to call it, these patient populations.
- 11:57SPEAKER_01: The second is you have periocytes, these are cells that wrap themselves around the retinal capillar endothelium.
- 12:03SPEAKER_01: They're important because they're the supportive cells of the retinal capillar endothelium.
- 12:06SPEAKER_01: They're the first cells that are lost actually in hyperglycemia.
- 12:09SPEAKER_01: So that's an important, I think, aspect to them.
- 12:11SPEAKER_01: And when they're lost, essentially, that's when vascular, the endothelial cells break down and are lost.
- 12:17SPEAKER_01: The third is mularglial cells and astrocytes.
- 12:20SPEAKER_01: These are cells that essentially provide the maintenance barrier function or norin to the actual cells in the vascular endothelium.
- 12:27SPEAKER_01: And we'll talk about that a little bit more in detail later, but those are important because they essentially hug the vessels and essentially provide a lot of the uh stressor agents that occur within those cells when there's any sort of end uh insult or injury.
- 12:41SPEAKER_01: And the final is the outer barrier or the RPE cells.
- 12:44SPEAKER_01: And that those RPE cells obviously line the end the outer retina, but the important part is they prevent it from the choroid and the leakage that could occur from the choroid essentially.
- 12:54SPEAKER_01: And that's more of obviously a function in neovascular AMD than in diabetic renopathy, but still yet important.
- 13:00SPEAKER_01: So again, these are all cells that are very important to the vascular endothelium.
- 13:05SPEAKER_01: This is the blood retinal barrier, this is how it's made up of this.
- 13:08SPEAKER_01: And and just to kind of give you a sense of what we're talking about here, when we talk about the blood retinal barrier, obviously the inner blood retinal barrier is the retinal vasculature, the outer retinal barrier is between the RPE and the choroid.
- 13:22SPEAKER_01: How does this stay closed?
- 13:23SPEAKER_01: Well, there's obviously a pathway called the wint-norin pathway.
- 13:27SPEAKER_01: Uh it's detailed here.
- 13:29SPEAKER_01: But essentially these are acting on the glial cells to essentially keep that maintenance of that blood retinal barrier closed in those cells.
- 13:36SPEAKER_01: And these act both on the retinovascular endothelium as well as on the retinal pigment epithelium cells that are there to keep essentially those cells closed in those patients.
- 13:46SPEAKER_01: In the middle, you have the common discussion we had just a moment ago about angiopuetin, ange 1 and TI-2 keep the cells quiet.
- 13:54SPEAKER_01: So you have a TI-2 agonist or an ange 1 drug you can give somebody that can also keep the vasculent quiet through the periocytes.
- 14:03SPEAKER_01: So different cells they're acting on, but it's doesn't essentially give you that.
- 14:06SPEAKER_01: But what happens essentially in these pathological states is to the right, which is when VEGF and angiopoin two open these cells, and essentially you have these stress glial cells and RPE cells.
- 14:17SPEAKER_01: And what what essentially, you know, how this all kind of transpired or done, obviously we can look at the stuff that's done in the labs, but um there's there's there's actually diseases which uh happen when patients using the Wint-Norin pathway, which is fever essentially, it's a pediatric disease, retinal disease.
- 14:36SPEAKER_01: And the idea was that Wint was essentially deficient in these patient populations.
- 14:40SPEAKER_01: So maybe giving patients an anti-Wint drug might be beneficial, and obviously the Wint in those patient populations is important.
- 14:48SPEAKER_01: So looking at that in that way was the reason why this sort of mechanistic activity came up.
- 14:53SPEAKER_01: You're all very familiar with this, so I'm not going to go to this in detail.
- 14:55SPEAKER_01: VEGF A is well known, we know what it does.
- 14:58SPEAKER_01: It breaks down the blood retinal barrier, causes leakage, permeability effects.
- 15:02SPEAKER_01: We've seen this all along.
- 15:04SPEAKER_01: So there's not really a whole lot to go into this.
- 15:06SPEAKER_01: But hypoxia and sort of hyperglycemia, they can all cause VEGFA sus uh expression in those patients.
- 15:13SPEAKER_01: And this is that second pathway, which I talked about, which is the Wint beta-catenin pathway.
- 15:18SPEAKER_01: This is again the maintenance program.
- 15:20SPEAKER_01: Again, it's important to understand that norine signaling is important in these diseases that can cause vascular development of the retina.
- 15:26SPEAKER_01: That's the disease I talked about just a moment ago.
- 15:28SPEAKER_01: But essentially, norin is the retina's own uh barrier of repair signal, and glial cells make this uh norin protein, and the endothelium need it to in order essentially to seal the vasculature off.
- 15:41SPEAKER_01: So important to understand essentially that these are essentially the ways in which the blood retinal barrier breaks down.
- 15:48SPEAKER_01: And we had learned more a little bit recently about this angiopuieten tie-2 axis, which is also very important.
- 15:54SPEAKER_01: Angiopuitin, obviously, too, is the bad actor.
- 15:58SPEAKER_01: This works essentially by uh signaling intracellularly down the VEGF receptor pathway, and angiopuitin II and VEGF together are essentially what causes vessels to destabilize and that blood retinal barrier break down both the inner retinal barrier and the outer retinal barrier.
- 16:13SPEAKER_01: We are uh emerging on some drugs that will be tied to agonists, which are going to be good for patients potentially.
- 16:19SPEAKER_01: But we also right now have angiopuitin 2 inhibitors, things like uh ferissimab, which is a drug that's commercially available right now.
- 16:27SPEAKER_01: That's an angiopoietin II inhibitor with a VEGF inhibitor.
- 16:30SPEAKER_01: So these are two uh opportunities for us to basically stop this pathway amongst many.
- 16:35SPEAKER_01: Um let me show you just a quick example of where this looks like in all these other kind of um uh uh sort of cytokines that are out there.
- 16:44SPEAKER_01: But you know, you can see that in the control patient and the diabetic retinopathy patient, you have loss of these periocytes due to hyperglycemia.
- 16:51SPEAKER_01: These pericytes essentially break down the blood retinal barrier.
- 16:54SPEAKER_01: You have the cells that are the vessels that are lost as a result of that, and then you have pruning of the vessels which occur over time.
- 17:00SPEAKER_01: So essentially the pericite density drops, and that's what causes the vascular entithelial loss.
- 17:05SPEAKER_01: But there's a variety of different other kind of shots on goal.
- 17:08SPEAKER_01: If you look at it from a drug development perspective, any of these could be opportunities.
- 17:12SPEAKER_01: So you could maybe, you know, and um uh provide semaphorin to patients, you know, you could uh inhibit PDGF.
- 17:19SPEAKER_01: There's obviously inflammatory cytokines we if we would look at right now with some of our uh IL-6 inhibitors which are coming online potentially for other diseases, but also because we use steroids in patients, and steroids can be a great inhibitor of these sort of things, but there are a variety of other different strats and goals that are there as well.
- 17:36SPEAKER_01: So with that, I'm gonna turn over to Dr.
- 17:38SPEAKER_01: Avery.
- 17:38SPEAKER_01: He's gonna take us through a second learning objective as well.
- 17:41SPEAKER_00: Thanks, Rishi.
- 17:42SPEAKER_00: Uh that's a great overview of these new pathways to discuss for treatment of the blood retinal barrier breakdown.
- 17:48SPEAKER_00: So, learning objective number two is to assess the rationale for the emerging therapeutic approaches targeting this uh blood retinal barrier, stability and vascular regulation in both DME as well as AMD.
- 17:59SPEAKER_00: Um, a question to start with.
- 18:02SPEAKER_00: Uh just to reiterate some of what you may have heard or what you know, a direct tie-two agonist is designed to do what?
- 18:28SPEAKER_00: All right, well, uh the the choice of to activate the tie-2 receptor directly, independent of how much ang one is around, is correct.
- 18:36SPEAKER_00: And you folks are, as Rishi said before, well educated.
- 18:40SPEAKER_00: That uh is because TI 2 is what ties the blood vessels together, and ange 1 sits on it and activates it.
- 18:48SPEAKER_00: So ang 2 competes for it, so uh it's a sort of an indirect way when you block ange 2, but tie 2 is the direct way of affecting the mechanism.
- 18:59SPEAKER_00: So let's talk a little bit about the landscape for the uh blood retinal barrier and what's there.
- 19:05SPEAKER_00: Um, there are several ways we can approach uh both macro generation and diabetic retinopathy, and of course, uh anti-VEGEF monotherapy has been approved for over 20 years, and that just removes the ligand VEGF that is quite important.
- 19:18SPEAKER_00: It's stimulating both neovascularization as well as vascular permeability.
- 19:22SPEAKER_00: In fact, it was called vascular permeability factor and clone separately, and uh they found out it's the same molecule.
- 19:29SPEAKER_00: But that is a very important component of VEGEF's activities.
- 19:32SPEAKER_00: The other uh way that's currently available and approved is a combination of ange2 inhibition as well as anti-vEGEF inhibition, and that's fursimab.
- 19:41SPEAKER_00: That takes the anti-vEGEF out and also is able to block the ANG-TI pathway indirectly by blocking ANG-2 and allowing uh a better amount of angge 1 to stimulate TI2.
- 19:54SPEAKER_00: Uh two investigational pathways that were mentioned.
- 19:57SPEAKER_00: One is to sort of reactivate the stabilizer, and that's the TI-2 direct agonism.
- 20:03SPEAKER_00: That's stimulating uh the TI-2 molecule or receptor directly, and there are antibodies to do that.
- 20:10SPEAKER_00: There's one called Tispectus, it's investigational.
- 20:13SPEAKER_00: It forms a pentamer of that uh TI-2 molecule and allows uh complete activation and may actually last longer than the uh indirect blockade of ANG2.
- 20:24SPEAKER_00: The other pathway that's uh new, as just mentioned, is the WENT pathway, and that works totally separate from the ANG2 thing.
- 20:32SPEAKER_00: This is the new uh drug uh remig remig, an easy one for me to say, I'm sorry.
- 20:38SPEAKER_00: But it's investigational as well, and that is something that mimics norin and activates the WENT pathway and uh stabilizes uh the blood retinal barrier by rebuilding the junctions.
- 20:51SPEAKER_00: So uh these different points of attack and differences between the ANG2 neutralization with anti-VEGF, which is furcimab, and the TI spectus, the investigational one with direct TI-2 agonism, what's the difference?
- 21:05SPEAKER_00: Well, it revolves around the TI-2 receptor itself being directly activated.
- 21:09SPEAKER_00: So, in the absence of angge 1, which can happen when you lack parasites, uh blocking angge 2 uh may not have much of an effect on the uh the TI-2 receptor because you actually, by blocking ang2, you're just allowing the angie 1 to stimulate the TI-2 receptor.
- 21:29SPEAKER_00: And so in the absence of a lot of ang1, the TI-2 antagonists, such as first remot, may not have a lot of added benefit.
- 21:37SPEAKER_00: Where would that potentially be important?
- 21:39SPEAKER_00: Well, paricytes.
- 21:40SPEAKER_00: When parasites are lost, uh, there may not be a lot of angon around.
- 21:44SPEAKER_00: And what is the first thing that happens in diabetic retinopathy?
- 21:47SPEAKER_00: One of the first things is loss of parasites.
- 21:49SPEAKER_00: So it's potentially more beneficial, we'll see, uh, to directly stimulate the Tai 2 molecule instead of indirectly stimulating it by blocking angine.
- 22:02SPEAKER_00: With respect to Climinal evidence, we know from the Versimab trials that we can get a little better drying than strict anti-VEGF alone with this combination of Fercimab.
- 22:15SPEAKER_00: Investigationally, there's the in RVO that has been published, the ROHA study, Rioja study, has shown some improvement that's pretty dramatic in a small number of patients using the direct tie II antagonism, agonism and the VEGF inhibitor.
- 22:31SPEAKER_00: Here's that data right here.
- 22:33SPEAKER_00: This is a a portion of this study of this Tispectus.
- 22:38SPEAKER_00: And the RVO patients are have been reported here in this case, and it was a really striking improvement of 16 to 17 letters and 157 microns of reduction in edema just at 12 weeks.
- 22:52SPEAKER_00: And very, very impressive using this combination of TI2 agonism as well as the anti-VEGF.
- 23:01SPEAKER_00: On the basis of this study, there are now four trials that are underway, two in each in macular generation and two in diabetic macular edema, looking at this antagonism of VEGF and agonism of Tai 2.
- 23:21SPEAKER_00: The Went Norn pathway is the other new pathway that we were talking about.
- 23:25SPEAKER_00: As as Rishi mentioned, you know, NORN is sort of missing in fever, this peripher this in this pediatric disease where you get exudation in the periphery.
- 23:35SPEAKER_00: And it's really interesting that we can look at this disease, find out what molecule is missing, and then go ahead and try to make a or mimic it with an antibody, a tetravalent antibody, and cure things like uh diabetic retinopathy and big diseases from studying a very rare disease.
- 23:52SPEAKER_00: Uh I like the concept of that.
- 23:54SPEAKER_00: And that's what's been done.
- 23:55SPEAKER_00: This uh pathway is is stimulating uh as though norin is being administered.
- 24:03SPEAKER_00: It's a, like I said, a tetravalent antibody, it binds the fissile forward, other areas as Rishi was showing, and it sort of stimulates the formation of the tight junctions and closes down and stabilizes the blood retinal barrier, independent of VEGF.
- 24:18SPEAKER_00: And uh that's the beauty of this particular uh pathway.
- 24:22SPEAKER_00: Interestingly, yesterday, the almost last, next to last uh paper of the entire retina subday uh was on the Brunello study, and it was shown that this uh drug itself uh was uh found to meet its primary endpoint, was non-inferior to randomizomab monthly uh in treating patients with diabetic retinopathy.
- 24:44SPEAKER_00: Uh both agents had uh statistically uh non-inferior improvement in visual acuity.
- 24:51SPEAKER_00: Uh what was interesting though is the number of PDR proliferative diabetic retinopathy complications were higher in the new WENT pathway, uh this uh remigorig uh pathway as opposed to randobismab, uh, in part because it doesn't block the VEGEF neovascularization.
- 25:10SPEAKER_00: VEGEF blocks that, but also blocks the vasoproliferative leakage.
- 25:15SPEAKER_00: But uh the WENT pathway is not exactly uh addressing the neovascularization as we see with anti-VEGEF.
- 25:23SPEAKER_00: Uh nevertheless, it meant this meets its primary endpoint and it has a lot of excitement amongst us retina specialists as a potential uh second way, second pathway to stop the leakage and the blood retinal barrier in patients, not with diabetes, maybe with other conditions as well, uh, when we're not seeing the kind of response we want with anti-VEGF alone.
- 25:44SPEAKER_00: Uh based on this study, uh there's one more the uh Barolo study should be reporting, I think the first quarter of next year.
- 25:51SPEAKER_00: Hopefully, it's a similar study, and then we're gonna have two, and they can file for approval.
- 25:56SPEAKER_00: Supertuscan, a third study, is being uh performed to look at both uh neovascular AMD and BRVO.
- 26:03SPEAKER_00: Um if we look at all these different uh approaches and what they do and what they lack, uh that's what this graph is uh trying to show here.
- 26:13SPEAKER_00: We're all familiar with uh monotherapy with anti-VEGEF.
- 26:17SPEAKER_00: It doesn't really directly affect the TI2 and pathway, nor does it affect the WINT pathway.
- 26:23SPEAKER_00: So it leaves those unaddressed.
- 26:24SPEAKER_00: It doesn't uh affect a lot of inflammatory pathways.
- 26:28SPEAKER_00: So even though this is a standard of care, it's really revolutionized our treatment of everything.
- 26:32SPEAKER_00: Uh there's a lot to be uh added to, we hope.
- 26:36SPEAKER_00: And uh so that's uh that's our standard we're sort of starting with.
- 26:40SPEAKER_00: I guess you could also say that uh fursimab, the second one here, is also a standard now.
- 26:44SPEAKER_00: It's uh probably the most commonly uh most expensive, uh the most uh well it's hugely used.
- 26:50SPEAKER_00: I think uh bebaccismab is still quite quite used, but the the sales of fursimab are the highest.
- 26:56SPEAKER_00: Um it has the added benefit of attacking the ange2 tai 2 sort of uh pathway.
- 27:03SPEAKER_00: But it also leaves the wind pathway alone and it doesn't really directly address inflammation, although indirectly it does.
- 27:10SPEAKER_00: Um and in diabetes it seems to be a little more effective in drying than in macular generation, possibly because there's more inflammation in other pathways in diabetes when compared to macular generation.
- 27:20SPEAKER_00: Um looking at the direct tie 2 agonism, which is the tyspectus, uh that just bypasses the problems where there might not be ange 1 around.
- 27:30SPEAKER_00: For instance, if there's a lack of pericytes or other conditions where the inhibition of angge 2 may not allow ang to then activate ty 2.
- 27:41SPEAKER_00: So it it is something that going directly to the source of the uh activation of the pathways is probably superior to blocking it indirectly via the ang2 inhibition of fersimab.
- 27:53SPEAKER_00: Uh that's the study that's still investigational, and uh we're awaiting those results.
- 27:59SPEAKER_01: Bob, uh just uh uh interrupt you, but there's a really great question that kind of pertains to this on the iPad.
- 28:04SPEAKER_01: So Ferrisimab already blocks ange 2.
- 28:06SPEAKER_01: What would direct tie 2 agonists add to the ange 2 blockade effect that doesn't occur right now?
- 28:11SPEAKER_00: Well, uh uh the thing it adds, or two things.
- 28:13SPEAKER_00: Uh looking at the molecule in preclinical studies, it has a longer duration.
- 28:17SPEAKER_00: It it really forms a pentamer that lasts longer than the ang2 blockade.
- 28:22SPEAKER_00: But this is all preclinical.
- 28:24SPEAKER_00: But what we uh also know is that when there's not a lot of ang-1 in the Melu, uh ang II blockade doesn't really do anything because it's it what it does is they compete for the receptor.
- 28:38SPEAKER_00: And so if you take out the angle, the ang 1 binds more than it stimulates tigh 2.
- 28:42SPEAKER_00: But if there's not a lot of angge 1 around, for instance, if you have no parasites making it, then blocking ang2 may not stimulate the uh TI-2 receptor, which is what gives you all the benefits.
- 28:53SPEAKER_00: So it it's it's remains to be seen.
- 28:56SPEAKER_00: We'll see with the studies how much better it is to block uh to stimulate the TI-2 receptor than block the angle receptor, but theoretically it has more promise and it seems to last longer from the preclinical data that I've looked at.
- 29:11SPEAKER_00: Yeah, great.
- 29:12SPEAKER_00: Okay.
- 29:13SPEAKER_00: Um the Wint or NORIN you know pathway we just mentioned, it's it's separate.
- 29:18SPEAKER_00: The disadvantage of it, it doesn't affect the neovascularization.
- 29:21SPEAKER_00: That's why we see more uh PDR in the trial just reported yesterday, affects a PDR.
- 29:27SPEAKER_00: Six percent or so of patients had a little uh either NV or some leakage, uh vitreous hemorrhage, for instance.
- 29:33SPEAKER_00: But um it does block a totally separate pathway addressing the blood retinal barrier, and so it will be a very nice adjunct, and we'll be able to attack the leakage from a totally separate mechanism after 20 years of being stuck with the only one mechanism.
- 29:47SPEAKER_00: Well, with the except for the NH2, so maybe not 20 years, but 15 years of only one and five years of the other.
- 29:54SPEAKER_00: Um corticosteroids are used when everything else fails right now.
- 29:58SPEAKER_00: The problem with corticosteroids, as we all know, is it can cause cataract as well as glaucoma.
- 30:03SPEAKER_00: Uh, it is a really good drying agent.
- 30:05SPEAKER_00: It does indirectly affect VEGF, and it takes out all these cytokines that are that are uh correlated with this diabetic macular edema.
- 30:15SPEAKER_00: It's just the problems with the glaucoma and the cataract, or else we might be using it as a primary treatment.
- 30:21SPEAKER_00: And so hopefully, with these other agents that don't seem to cause cataract or glaucoma, we'll be able to see achieve something similar.
- 30:28SPEAKER_00: And then finally, sustained delivery is very important.
- 30:31SPEAKER_00: Uh there is the uh port delivery system, which allows uh randomismab to be given for an extended period of time, and that does work as well, but they have to go to the operating room.
- 30:41SPEAKER_00: It's really only being used now in very needy patients, I would say.
- 30:45SPEAKER_00: But uh we're interested in all these different ways of extended delivery for all of our agents.
- 30:51SPEAKER_00: Uh so let's go forward to the learning objective three uh to identify patients with DME or neovascular AMD who demonstrate some optimal anti-VEGF response to inform timely evidence-based management strategies.
- 31:03SPEAKER_00: So we'll start with this patient, Carlos, who's a 67-year-old Hispanic man with type 2 diabetes.
- 31:09SPEAKER_00: Uh his vision is good at baseline 2030 and 2025.
- 31:13SPEAKER_00: He has some center-involved DME OD greater than OS.
- 31:17SPEAKER_00: Um, he underwent a lot of bevisimab injections, 11 before he was changed.
- 31:23SPEAKER_00: This was partly due to insurance.
- 31:25SPEAKER_00: Uh he's changed to randobismab and then a flibercept.
- 31:28SPEAKER_00: And during that time, his vision dropped in the right eye to 2030 to 2060.
- 31:33SPEAKER_00: His left eye responded well uh uh to this.
- 31:37SPEAKER_00: He was then changed to ferrisimab and still had persistent fluid.
- 31:42SPEAKER_00: He finally had a dexamethasone implant, but had uh a little baseline cataract that got worse, and uh he then was changed to ferismab and still was unable, we were unable to flatten his retina.
- 31:54SPEAKER_00: This is his baseline fluorescene angiogram, a little bit of NVD in the left eye, but you can see a lot of scattered microaneurysms uh uh present.
- 32:04SPEAKER_00: This was on presentation, he had some macular edema essentially with the heart exudates you see, no drill.
- 32:12SPEAKER_00: This looks very good.
- 32:13SPEAKER_00: This looks like you could get a good outcome, and again, his vision was fairly good at this time.
- 32:17SPEAKER_00: The problem is uh this is one of my partner's patients, there's just no way to dry this out with all those injections that kept getting worse.
- 32:26SPEAKER_00: Here was the Azerdex implant.
- 32:28SPEAKER_00: Uh, you can see it back there.
- 32:29SPEAKER_00: Sometimes that happens, and you can see a little sercinate ring, and the photo's a little dark, but there is some lipid uh in the superior macula.
- 32:36SPEAKER_00: Uh and finally, this is just from two weeks ago, uh, after another 10 personab injections, he had 20-something injections altogether and still has this persistent edema centrally.
- 32:48SPEAKER_00: Here you can see there's some uh drill off to the side.
- 32:51SPEAKER_00: It's not uh it's a little perplexing that he's so uh poorly responsive, but this is a patient that would really benefit, I think, from another mechanism of treating the blood retinal barrier.
- 33:06SPEAKER_00: I also think when you get to this sort of stage, uh there was a uh, you know, uh uh a lot of microaneurisms that were present.
- 33:14SPEAKER_00: Sometimes when the edema is off-axis like this, uh I'm going off script a little bit, I tend to pull out my laser.
- 33:20SPEAKER_00: I don't do it very often.
- 33:21SPEAKER_00: I I used to, this is I'm so old, we used to only have laser to treat these patients.
- 33:26SPEAKER_00: But this is a patient with the surcenate ring off axis uh with persistent edema.
- 33:31SPEAKER_00: I think this is probably the only time I'd ever dust off the laser of someone like this.
- 33:36SPEAKER_00: But basically, for the vast majority of patients, we don't even consider laser, and I think this is a great example of someone that would benefit from attack of one of these other pathways uh for uh repair of the blood retinal barrier.
- 33:50SPEAKER_00: Um, sort of discussing a bit more about the uh the different responses, as Vishy was mentioning, he spent some time trying to figure out who's a good responder, who's a non-responder.
- 34:03SPEAKER_00: It's a very difficult situation, in my opinion, because uh every case is a little bit different, and there are different things involved in this.
- 34:11SPEAKER_00: There's the amount of reduction of fluid.
- 34:13SPEAKER_00: Here it says a good responder is greater than 75% reduction in central retinal thickness from baseline.
- 34:19SPEAKER_00: Uh yeah, that's a good responder, uh, I think.
- 34:22SPEAKER_00: There's a really good responder, uh, you know, but I think they should be looking at the you know excess retinal thickness, because if you start at 500 microns and you lose 75 microns, you're at 125 micron edema, that's not a healthy retinal thickness.
- 34:35SPEAKER_00: So, you know, I I think even trying to simplify this, there are problems with these sort of uh w definitions.
- 34:42SPEAKER_00: And so there really is no universal one.
- 34:44SPEAKER_00: It also depends on what the vision is.
- 34:46SPEAKER_00: And it uh it may depend in some people on how frequently you get your injections.
- 34:50SPEAKER_00: What if you do well but you require injections every three or four weeks?
- 34:53SPEAKER_00: So there are different components that one can consider in uh what makes a a poor responder or a good responder or a non-responder.
- 35:03SPEAKER_00: But as Rishi said, it's pretty universal uh the non-responder, you know, when you're losing vision and you don't have change in the thickness, or it's a minimal change, then that's that's a bad or non-responder.
- 35:13SPEAKER_00: But these are important to try to identify, to try to study those patients, because those are the patients that are poor responders.
- 35:21SPEAKER_00: I think these new pathways will be most important for them.
- 35:24SPEAKER_01: I wanted to pause because again, there's a great question.
- 35:26SPEAKER_01: You get you get questions right before you get to the slide, which is really pertinent.
- 35:29SPEAKER_01: Thank you.
- 35:30SPEAKER_01: Uh yeah.
- 35:30SPEAKER_01: So at what point do you stop calling it slow to respond and start calling it non-response?
- 35:34SPEAKER_01: Is three injections really enough to decide?
- 35:36SPEAKER_01: What are your thoughts on three injections?
- 35:38SPEAKER_01: You think that's enough to decide?
- 35:39SPEAKER_00: I don't think it I don't think there's their data from from the Random Web study where they looked at, you know, because they were treating people and they had no choice, that you could actually see continued improvement at ZICs and even beyond.
- 35:52SPEAKER_00: So I think that's a little too early to call it.
- 35:55SPEAKER_00: Do I think it's too early to maybe change to another one?
- 35:58SPEAKER_00: No.
- 35:58SPEAKER_00: If you're not seeing any response, I I'm willing to change to another one, but I'm not willing to call them a non-responder to anti-VAGF.
- 36:06SPEAKER_00: Maybe they're not responding sufficiently to that agent.
- 36:09SPEAKER_00: And so degree more.
- 36:11SPEAKER_00: Okay.
- 36:11SPEAKER_00: Well, I can say this is a good response, because this is what a good response should look like.
- 36:15SPEAKER_00: Lots of swelling, poor vision, going to 2020, and not much edema.
- 36:20SPEAKER_00: So this is an easy call.
- 36:22SPEAKER_00: Uh, although some people say, well, there's still some uh edema.
- 36:25SPEAKER_00: We actually tolerate a little cystic edema with good vision in diabetes, I think, more than we do in macula generation.
- 36:31SPEAKER_00: But this is a good response.
- 36:32SPEAKER_00: Uh now, what are you looking for in the way of sort of biomarkers as to what a good response is going to be?
- 36:40SPEAKER_00: Who's gonna respond well?
- 36:41SPEAKER_00: Who do you have to worry about?
- 36:43SPEAKER_00: There are several things we look at.
- 36:44SPEAKER_00: Drill was mentioned by Rishi, and that's something that's disorganization of the inner retinal layers.
- 36:50SPEAKER_00: Uh, you can see it in the box to the right here.
- 36:53SPEAKER_00: I mean, it is a problem.
- 36:54SPEAKER_00: It is something that uh when the inner retina is disorganized, it correlates with poor visual outcome.
- 37:02SPEAKER_00: And you can say the same for easy disruption.
- 37:04SPEAKER_00: Um we've learned a lot more about the easy and macular degeneration, but it is something that correlates with visual loss and diabetes as well.
- 37:13SPEAKER_00: Um, and you know, the hyperreflective foci, these tiny little white dots that you can see illustrated here, uh, we see them an awful lot.
- 37:21SPEAKER_00: I used to think they were probably lipid, I couldn't see, but really they're not.
- 37:24SPEAKER_00: These are, you know, areas of inflammation often around glial cells.
- 37:28SPEAKER_00: And to me, it means that this is a patient that might benefit from a uh uh steroid injection.
- 37:33SPEAKER_00: And the patient, I forgot to mention it, the patient that had the Ozordex, the hyperreflective foci decreased from the pre-azordex to the post-azordex, but the thickness was still there.
- 37:43SPEAKER_00: But I I do think this is another biomarker that would indicate that a second pathway other than anti-vEGEF may be beneficial on this person.
- 37:51SPEAKER_00: And you know, we we we sort of see these in diabetes a lot.
- 37:56SPEAKER_00: Um this is an interesting thing about could there be a wrong target with just anti-vEGEF?
- 38:02SPEAKER_00: Uh, this is a busy slide on the left, but what was done in this study of non-responders, they measured the levels of these cytokines after an injection of anti-VEGEF.
- 38:14SPEAKER_00: And the first column, the first little graph to the top right is VEGEF really decreased over time after an anti-VEGEF injection.
- 38:22SPEAKER_00: No surprise.
- 38:23SPEAKER_00: But what was interesting is all of these other cytokines did not.
- 38:26SPEAKER_00: They remain elevated.
- 38:28SPEAKER_00: You know, ANG2, IL-6, you know, CAM, all these, all these other cytokines that are things that are targets for maybe steroids or maybe some of our other agents remained elevated.
- 38:39SPEAKER_00: So, you know, if you have a non-responder and you're giving them anti-VEGF uh, you know, and expecting it to fix everything, it could be related to these other cytokines, which are signs of inflammation and signs of other pathways being active.
- 38:55SPEAKER_00: And that's uh one of the reasons I think that we need these second uh adjunctive pathways.
- 39:03SPEAKER_01: Exactly right.
- 39:03SPEAKER_01: I I agree.
- 39:04SPEAKER_01: I you know this is like the fingerprint I hope we had for patients.
- 39:08SPEAKER_01: You know, I think when we talk about personalizing treatment options and we look at this, you know, maybe if we could do aqueous sampling on all patients or vitreous sampling, we get a better sense of how to personalize the treatment approach.
- 39:18SPEAKER_01: This is one of the most difficult ones to figure out.
- 39:20SPEAKER_00: And that's why the hyperreflective foci, I think, are a signal that these cytokines may be elevated.
- 39:27SPEAKER_00: It's not correlated perfectly, and the response isn't correlated perfectly.
- 39:30SPEAKER_00: That's something you do without a needle.
- 39:32SPEAKER_00: You can look for the hyperreflective foci, and then I I I feel that the uh other than VEGF pathways are more likely to be helpful in those patients.
- 39:41SPEAKER_00: Um let's shift to macro generation.
- 39:43SPEAKER_00: This is a 74-year-old patient of ours that had good vision on presentation.
- 39:47SPEAKER_00: He had a little cataract, he had an epiretinal membrane and a pseudo hole, actually in both eyes.
- 39:52SPEAKER_00: But uh I'll show you his picture, and despite the vision of 2030, uh he has uh uh something going on and received multiple injections.
- 40:01SPEAKER_00: Uh let me go ahead and show.
- 40:03SPEAKER_00: Here's uh his right eye at the top just has a pseudo-hole and mild epiretinal membrane.
- 40:08SPEAKER_00: Uh, but the left eye on the bottom panel, you can see uh pigment epithelial detachment.
- 40:13SPEAKER_00: You see some shrimp which is a subretinal hyperreflective material right over the pigment epithelial detachment.
- 40:19SPEAKER_00: If you follow the RPE and follow it into the PED, shall we say, you can still see this sort of above that, this sort of whitish material.
- 40:28SPEAKER_00: Shrim is very interesting in that, you know, it's sort of a descriptive term.
- 40:32SPEAKER_00: It could represent things like blood or it could be fibrous fibrin, it could be neovascular tissue with leakage.
- 40:39SPEAKER_00: It's it's not just a morph, it's it's a it's a descriptive term on OCT, but it does have importance because it can mean that this, if it doesn't go away, could uh correlate with poor vision, and discoform scars have that same sort of appearance down the road.
- 40:54SPEAKER_00: So when I say shrimp I'm usually fairly aggressive with the patient.
- 40:57SPEAKER_00: And this person uh was treated not by me, but one of my partners, fairly aggressively.
- 41:02SPEAKER_00: Um I'll show you the next sort of slide.
- 41:04SPEAKER_00: Here is after, you know, seven monthly more or less randomizer injections, it's uh it's still good vision, but it doesn't look any better, and the shrimp's even more noticeable.
- 41:14SPEAKER_00: Uh and you still have intrarretinal edema and you still have the uh PED.
- 41:19SPEAKER_00: And you know, there is this mild epiretinal membrane, but having treated a lot of these things, the epiretinal membranes that that really I think need to be removed uh to flatten these things, I think need to be worse than this.
- 41:31SPEAKER_00: I mean, it's true they may inhibit the retinal fluid from drying out completely, but with respect to vision, I think that's not the problem here.
- 41:40SPEAKER_00: I think it's this trim here on top of the RPE.
- 41:43SPEAKER_00: Uh fast forward, after 15 parissimabs and and another 18 of fliberceps, this is only done because the vision is still uh 2080, which, you know, uh after that amount of uh time uh is sort of surprising with this sort of uh larger area of shrimp that is still present and there's still active uh edema, intra-retinal cystic edema in the center, and even some subretinal fluid off to the side.
- 42:14SPEAKER_00: So this patient, despite very aggressive and prolonged treatment, is uh, I would say a non-responder.
- 42:21SPEAKER_00: I mean, you know, vision's getting worse.
- 42:24SPEAKER_00: Uh if you stop treating, it gets a heck of a lot worse.
- 42:26SPEAKER_00: Some of the treatments every four, some every seek, they six weeks average every five.
- 42:31SPEAKER_00: But uh, this is a very needy patient.
- 42:33SPEAKER_00: This is what we call a frequent flyer in our practice.
- 42:35SPEAKER_00: And yet we're still maintaining uh decent, not great, but decent vision for what you see for the duration of this.
- 42:43SPEAKER_00: And here he is just uh two weeks ago in our practice.
- 42:47SPEAKER_00: Uh this is a different uh scan for uh uh AI reasons, but it's uh more compressed.
- 42:53SPEAKER_00: But uh still cystic edema in the center and uh the shrimp.
- 42:57SPEAKER_00: And after a couple years like this, this shrimp may not go away.
- 43:02SPEAKER_00: It you know, uh it it has on the on the omphos to the left, it it looks like it has a little bit of fibrosis starting to the side, but there's still activity here.
- 43:12SPEAKER_00: And this is not someone, if we give up on this, I'm sure the vision will quickly go down to 2400 or count fingers.
- 43:17SPEAKER_00: So this patient is still being treated, but this is a good example of an accuration patient that's not responding as well as we'd like.
- 43:27SPEAKER_00: And so, again, a good example of someone who would benefit from uh another pathway to uh try to uh treat this disease.
- 43:38SPEAKER_00: Um so uh let's go to uh another question.
- 43:42SPEAKER_00: Um, and there's maybe no right or wrong answer to this, but uh which finding on this OCT do you think most strongly predicts that vision will not recover regardless of further anti VEGF treatment?
- 44:13SPEAKER_00: Alright, so let's see.
- 44:14SPEAKER_00: We have uh the majority pick this uh the subretinal hyperreflector material or early fibrosis.
- 44:20SPEAKER_00: I think that's a very reasonable answer.
- 44:22SPEAKER_00: Uh you know, we'll start at the top.
- 44:24SPEAKER_00: You know, increasing subretinal subretinal fluid sometimes is correlated with decent outcomes, so that's not one.
- 44:30SPEAKER_00: Persistent intratinal fluid, I agree, it's not the cause because sometimes we have edema and still have good vision.
- 44:37SPEAKER_00: It means you're still active, but it doesn't necessarily mean you're gonna have uh crappy vision.
- 44:42SPEAKER_00: Um the uh uh RPE, you know, you can see good vision over RPEs even when they grow.
- 44:48SPEAKER_00: Uh the outer retinal atrophy and ellipsoid zone loss, that's sort of a permanent thing, and we did see some of that in that patient, so I think that's a reasonable answer too.
- 44:57SPEAKER_00: But I would say the last two are the the best answers for this, these two.
- 45:01SPEAKER_00: Um so re the the other thing we we should like to get across is sort of a a pathway to evaluate these patients and what to do with not just the current uh drugs we have, but what to do in the future when we have more options.
- 45:19SPEAKER_00: Uh the first thing I think I would like to get across is adequate treatment in with respect to the intervals.
- 45:27SPEAKER_00: That's the hardest thing I see with some of my satellites where people are very busy, uh, where people really don't get monthly treatment initially when you're trying to make sure someone's a responder or not.
- 45:39SPEAKER_00: And so the point is to just make sure that the people, before you call them a non-responder, they get an adequate uh chance with a with a monthly uh uh series of injections before you feel that they have failed and have to go to a switch.
- 45:57SPEAKER_00: And then we do have the ability to switch to other treatments.
- 46:00SPEAKER_00: We can go from anti-veg F alone to anti-VEGF with, you know, platelet drive, I mean sorry, um placental growth factor, which is uh flibercep.
- 46:08SPEAKER_00: Uh so there is a switch from just one anti-veg F, but there's another switch that could be done to Fersimab, which has the H2 TI2 pathway as well.
- 46:17SPEAKER_00: So changing to that or even to this uh the port delivery system for very continual dosing, there are some ways we can change, you know, uh without all these second pathways that we hope to have uh soon.
- 46:31SPEAKER_00: And then the other thing is when things aren't going well, uh, you know, you you may want to evaluate and try to figure out are you missing something?
- 46:39SPEAKER_00: Could it be vitrio macular traction?
- 46:41SPEAKER_00: Could the epiretinal membrane be causing trouble?
- 46:43SPEAKER_00: Do you need surgery for things like that?
- 46:45SPEAKER_00: Or put someone in a trial for one of these new agents.
- 46:48SPEAKER_00: So there are other alternatives uh beyond just what we have in our in our clinic uh today.
- 46:55SPEAKER_00: Um So um did you want to take a look?
- 47:00SPEAKER_01: Nice job, Bob.
- 47:00SPEAKER_01: Thank you for the really nice.
- 47:02SPEAKER_01: So these are sort of like four things I think hopefully we've communicated tonight, because we're gonna get to the question and answer portion in just a second.
- 47:09SPEAKER_01: So uh rule out as as Bob said, not enough drug first, or you know, the mechanism not being qualified.
- 47:15SPEAKER_01: I think again, loading the patient completely is important.
- 47:18SPEAKER_01: Um, you know, we can talk about when we switch patients, we really load them or not, maybe the QA.
- 47:23SPEAKER_01: Um, the wrong target.
- 47:24SPEAKER_01: You know, we talked about the fingerprinting of patients, right?
- 47:27SPEAKER_01: So we saw the cytokine action of patients within the uh sampling that was done and saw those differences as far as you know, VEGF suppression was there, but maybe the other cytokines were sort of left unmatched.
- 47:38SPEAKER_01: Uh too late, you know, defining whenever a patient is not responding or objectively, we have some really good data now to say after three injections, maybe if you use a definition of five letters of gain or 10% reduction in retinal thickness is a starting point.
- 47:52SPEAKER_01: It's not perfect, but it's a limited early response, at least in those patient populations.
- 47:56SPEAKER_01: And again, we have some really great data that's coming out most recently.
- 47:59SPEAKER_01: We saw the Brunello data presented here, Academy.
- 48:02SPEAKER_01: I hope you caught the presentation.
- 48:03SPEAKER_01: If you didn't, it's on the Academy app actually already.
- 48:05SPEAKER_01: You can see it uh uh uh in a virtual format.
- 48:09SPEAKER_01: And it really tells you about what WINT agonism might do for patients with diabetic macledema.
- 48:14SPEAKER_01: The outcomes were pretty impressive, albeit you know, obviously that we saw some aspects of it that were not VEGEF really mediated, and then we're gonna need to map, you know, match that with our agents at hand.
- 48:26SPEAKER_01: So there's a really good, I think, good four take-home points from today's program.
- 48:30SPEAKER_01: Um happy to go into question and answer.
- 48:32SPEAKER_01: We have a couple of questions here, but before I do, um, you know, I think that there's some information that you can put into action, um, talk, would look through your charts maybe when you go back and see are you really getting the outcome that you hope to achieve?
- 48:44SPEAKER_01: We talked about this a little bit more, but three loading injections, are you doing that in all of your patients?
- 48:49SPEAKER_01: I think that that obviously has been shown to be beneficial into many patients versus those who weren't loaded.
- 48:55SPEAKER_01: The second is looking at sort of this definition criteria.
- 48:58SPEAKER_01: The third is um ask patients about, you know, whether they're or even find out if they're aware of these emerging therapies, because I think it's important for us to educate our audience and our patients on potentially emerging therapies as they come about.
- 49:10SPEAKER_01: And uh again, looking at the OCT features that bear uh potentially poor or good prognosis, I think it's important to kind of get yourself educated on those sort of activities.
- 49:19SPEAKER_01: Um, there's some additional resources uh that are available at cmeoutfitters.com uh for more educational activities, and there's an ophthalmology hub as well.
- 49:28SPEAKER_01: So uh the first question is a good one.
- 49:30SPEAKER_01: Uh you after you do about five to six injections on a 40-year-old patient with diabetes with diabetic retinopathy and macledema who's responding well, is it reasonable to switch to laser in that patient, maybe for more durability?
- 49:41SPEAKER_01: Has there been any studies on laser and sort of the adjunct of laser and sort of durability potentially?
- 49:48SPEAKER_00: Well, you talk about DMEK.
- 49:50SPEAKER_00: Yeah.
- 49:50SPEAKER_00: Because you know, we all uh a lot of us have started using PRP in addition for treating PDR because of the noncompliance issue and whatnot.
- 50:00SPEAKER_00: But um, as I mentioned in in my case, I think when you have a sercinate lipid ring with juicy microaneurysms off-axis and the edema seems to be coming from that area, I do recommend laser for that.
- 50:12SPEAKER_00: The uh typical grid laser that we used to do before anti-VEGF and in the area of swelling, I I just I I just don't ever do that anymore.
- 50:22SPEAKER_00: Um but I do think that uh that that people do add laser within our practice.
- 50:28SPEAKER_00: Uh several of my doctors do do it not routinely, but a lot more frequently than I do, uh, especially in people who are not responding all the way.
- 50:38SPEAKER_00: But if you have a good response and um it depends on a lot of things, like the where it is, where the what the microanions looks like, what what what the vision is and where the edema is.
- 50:49SPEAKER_00: Uh so it's hard to generalize, but uh I just would do it on a case-by-case basis.
- 50:54SPEAKER_01: Uh this is uh another good question from the audience member.
- 50:56SPEAKER_01: What's the ideal patient for remigarig and uh based upon the data we've seen to date, are you looking for anything specifically in future releases a response to VEGF experience patients?
- 51:06SPEAKER_01: So we obviously saw the data for the the newest uh drug uh that we were look talking about this evening on WINT agonism.
- 51:14SPEAKER_01: Uh really impressive results, equivalent to a rhenabismab uh given 0.5 given monthly, essentially one year.
- 51:21SPEAKER_01: Um we haven't seen some of the subgroup analyses yet, but is there an ideal patient, Bob, you'd sort of look at potentially and look at this?
- 51:28SPEAKER_01: I think we we don't know yet, I think is the answer.
- 51:30SPEAKER_00: We don't know much about using it in conjunction with anti-VEGF, but I think that would be an ideal patient, someone who's on anti-VEGF and is not responding and has uh a lot of fluid, maybe also has a lot of you know hyperreflective oci or things that I can guess the data will show.
- 51:46SPEAKER_00: We'll do subgroup analysis and figure it out.
- 51:48SPEAKER_00: But I would I would think it will be used the ideal patient is someone who's already on anti-VEGF and is not responding uh adequately with their edema.
- 51:58SPEAKER_00: Um that's and you know maybe there are other uh cytokin uh I'm sorry, other sort of biomarkers showing me that it works better in this population, for instance, hyperreflective oci or whatever, maybe I don't know.
- 52:11SPEAKER_00: But I think that's the ideal patient I would use it in right away.
- 52:14SPEAKER_01: Great.
- 52:15SPEAKER_01: Thank you, Bob, for participating in this program.
- 52:17SPEAKER_01: Thank you all for coming this evening, and thank you all watching virtually at home.
- 52:21SPEAKER_01: I appreciate your interest, and uh we'll conclude the program for this evening.
- 52:25SPEAKER_01: Thank you.
- 52:25SPEAKER_01: Thank you, everyone.